Landiolol

Drug Profile

Landiolol

Alternative Names: Corebeta; Low-dose landiolol; ONO-1101; Onoact; Onoact 50

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Arrhythmias; Coronary disorders; Supraventricular tachycardia
  • Phase II/III Atrial fibrillation; Atrial flutter; Ventricular arrhythmias

Most Recent Events

  • 10 Nov 2017 Ono pharmaceutical plans the J-Land 3S phase II/III study for Tachycardia in Japan (JapicCTI-173767)
  • 01 Mar 2016 Ono Pharmaceutical initiates enrolment in a clinical trial for Coronary disorders (Diagnosis) in Japan (UMIN000020432)
  • 01 Jun 2015 Phase-II/III clinical trials in Ventricular arrhythmias in Japan (IV) (JapicCTI-152956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top